A novel clinically applicable biomarker for testing HRD status based on the mutational signatures: Results for the phase 2 trial of olaparib maintenance monotherapy in patients with primary high-grade ovarian carcinoma-MedSci.cn

A novel clinically applicable biomarker for testing HRD status based on the mutational signatures: Results for the phase 2 trial of olaparib maintenance monotherapy in patients with primary high-grade ovarian carcinoma

Oda, K; Nishijima, A; Hasegawa, K; Sato, S; Kato, K; Mori, M; Nagao, S; Matsumura, N; Kagabu, M; Takenaka, M; Yoshihara, K; Konno, Y; Hamanishi, J; Tokunaga, H; Ogasawara, A; Ueda, K; Kashiwabara, K; Aoki, T; Nishimura, K; Tatsuno, K; Aburatani, H

GYNECOLOGIC ONCOLOGY, 2023; 176 (): S297

科室
- - 订阅+
  - 更多科室
工具
服务